
LGALS3BP Rabbit pAb

Catalog Number: bs-5729R

Target Protein: LGALS3BP

Concentration: 1mg/ml

Form: Liquid

Host: Rabbit

Clonality: Polyclonal

Isotype: IgG

Applications: WB (1:500-2000), IHC-P (1:100-500), IHC-F (1:100-500), IF (1:100-500), ELISA (1:5000-10000)

Reactivity: Human (predicted:Mouse)

Predicted MW: 63 kDa

Entrez Gene: 3959

Swiss Prot: Q08380

Source: KLH conjugated synthetic peptide derived from human LGALS3BP: 351-450/585.


Purification: affinity purified by Protein A

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: LGALS3BP is a ligand of galectin 3, and has been suggested to influence tumor proliferation and metastasis formation. Galectins and their ligands have been implicated in cell transformation and cancer metastasis, and found to have prognostic value. LGALS3BP also known as Mac 2 BP, and as 90K, is a highly glycosylated, secreted protein extensively studied in human cancer, which binds galectin 1, galectin 3 and galectin 7. High expression levels of this molecule are associated with a shorter survival, the occurrence of metastasis or a reduced response to chemotherapy in patients with different types of malignancy. The mechanisms underlying the prognostic significance of 90K and galectins in cancer are far from being understood, although they may be related to the ability of these proteins to interact and, to some extent, modulate cell cell and cell matrix adhesion and apoptosis.

VALIDATION IMAGES



25 ug total protein per lane of various lysates (see on figure) probed with LGALS3BP polyclonal antibody, unconjugated (bs-5729R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.